Neuropeptide Y administration reverses tricyclic antidepressant treatment-resistant depression induced by ACTH in mice

Hormones and Behavior

Volumn 73, Issue , 2015, Pages 56-63

  Antunes, Michelle S ^a   Ruff, Jossana Rodrigues ^a   de Oliveira Espinosa, Dieniffer ^a   Piegas, Manuela Bastos ^a   de Brito, Maicon Lenon Otenio ^a   Rocha, Kellen Athaíde ^a   de Gomes, Marcelo Gomes ^a   Goes, André Tiago Rossito ^a   Souza, Leandro Cattelan ^a   Donato, Franciele ^a   Boeira, Silvana Peterini ^a   Jesse, Cristiano R ^a  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

BDNF; Hypothalamic pituitary adrenocortical; Indoleamine 2,3 dioxygenase; Kynurenine; Neurotrophins; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CORTICOTROPIN; IMIPRAMINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; FORCED SWIM TEST; HIPPOCAMPUS; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; SWIMMING;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CORTICOSTERONE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; MICE, INBRED C57BL; NEUROPEPTIDE Y; SWIMMING;

EID: 84935505335     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2015.05.018     Document Type: Article

References (46)

1. Arborelius L., Owens M.J., et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 1999, 160:1-12.
2. Bahi A., Dreyer J.L. Hippocampus-specific deletion of tissue plasminogen activator "tPA" in the adult mice impairs depression- and anxiety-like behaviors. Eur. Neuropsychopharmacol. 2012, 22:672-682.
3. Cardona A.E., Pioro E.P., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006, 9:917-924.
4. Corona A.W., Huang Y., et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J. Neuroinflammation 2010, 7:93.
5. Corona A.W., Norden D.M., et al. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX3CR1)-deficient mice. Brain Behav. Immun. 2013, 31:134-142.
6. Crowther J.R. ELISA. Theory and practice. Methods Mol. Biol. 1995, 42:1-218.
7. Dos Santos V.V., Santos D.B., Lach G., Rodrigues A.L., Farina M., De Lima T.C., Prediger R.D. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice. Behav. Brain Res. 2013, 244:107-115.
8. Dunn A.J., Welch J. Stress- and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend on sympathetic nervous system activity. J. Neurochem. 1991, 57:1615-1622.
9. Fujiwara M., Shibata M., et al. Formation of 5-hydroxykynurenine and 5-hydroxykynurenamine from 5-hydroxytryptophan in rabbit small intestine. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:11.
10. Gibney S.M., McGuinness B., et al. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 2013, 28:170-181.
11. Grah M., Mihanovic M., et al. Brain-derived neurotrophic factor as a suicide factor in mental disorders. Acta Neuropsychiatr. 2014, 13:1-8.
12. Guillemin G.J., Smythe, et al. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
13. Harkin A., Shanahan E., et al. Methylenedioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. Eur. J. Neurosci. 2003, 18:1021-1027.
14. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
15. Heim C., Newport C.J., et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000, 284:593-597.
16. Heyes M.P., Quearry B.J., et al. Systemic endotoxin increases l-tryptophan, 5-hydroxyindoleacetic acid, 3-hydroxykynurenine and quinolinic acid content of mouse cerebral cortex. Brain Res. 1989, 491:173-179.
17. Inoue T., Tsuchiya K., et al. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol. Biochem. Behav. 1994, 49:911-920.
18. Jiménez-Vasquez P.A., Diaz-Cabiale Z., Caberlotto L., Bellido I., Overstreet D., Fuxe K., Mathé A.A. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur. Neuropsychopharmacol. 2007, 17:298-308.
19. Kitamura Y., Araki H., et al. Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol. Biochem. Behav. 2002, 71:63-69.
20. Kormos V., Gaszner B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides 2013, 47:401-419.
21. Lang U.E., Hellweg R., et al. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol. Psychiatry 2007, 62:530-535.
22. Laske C., Banschbach S., et al. Exercise-induced normalization of decreased BDNF serum concentration in elderly women with remitted major depression. Int. J. Neuropsychopharmacol. 2010, 13:595-602.
23. Machado D.G., et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:642-650.
24. Martinowich K., Manji H., et al. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 2007, 10:1089-1093.
25. Mathew S.J. Treatment-resistant depression: recent developments and future directions. Depress. Anxiety 2008, 25:989-992.
26. Miller G.E., Chen E., et al. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol. Bull. 2007, 133:25-45.
27. Nemeroff C.B. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry 1996, 1:336-342.
28. O'Connor J.C., Lawson M.A., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
29. O'Connor J.C., Lawson M.A., et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212.
30. Olesen M.V., Christiansen S.H., Gotzsche C.R., et al. Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity. Neuropeptides 2012, 46:71-79.
31. Pandey G.N., Dwivedi Y., et al. Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatry 2002, 159:419-429.
32. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2003, Academic Pres, San Diego. 2nd ed.
33. Porsolt R.D., Le Pichon M., et al. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
34. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 463:3-33.
35. Rodrigues A.L.S., Da Silva G.L., et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci. 2002, 70:1347-1358.
36. Rotzinger S., Lovejoy D.A., Tan L.A. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010, 31:736-756.
37. Sajdyk T.J., Johnson P.L., et al. Neuropeptide Y in the amygdala induces long term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 2008, 28:893-903.
38. Salazar A., Gonzalez-Rivera B.L., et al. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 2012, 62:202-209.
39. Schule C., Baghai T.C., et al. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert. Rev. Neurother. 2009, 9:1005-1019.
40. Schwarcz R., Bruno J.P., et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
41. Shi C.G., Wang L.M., et al. Intranasal administration of nerve growth factor produces antidepressant-like effects in animals. Neurochem. Res. 2010, 35:1302-1314.
42. Sono M. The roles of superoxide anion and methylene blue in the reductive activation of indoleamine 2,3-dioxygenase by ascorbic acid or by xanthine oxidase-hypoxanthine. J. Biol. Chem. 1989, 264:1616-1622.
43. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995, 270:593-598.
44. Von Richthofen S., Lang U.E., et al. Effects of different kinds of acute stress on nerve growth factor content in rat brain. Brain Res. 2003, 987:207-213.
45. Wittchen H.U., Jacobi F., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:655-679.
46. Zhu C.B., Blakely R.D., et al. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.